Zanubrutinib in WM – The Phase 3 ASPEN Trial

Slide kit outlining the long-term follow-up of the ASPEN trial: Zanubrutinib vs. ibrutinib in patients with Waldenström’s macroglobulinemia (WM).

Slide-Kit
24 May 2024

tys/[ 1; &z Ez%?ohsH%h[ uuB)2v^AB)Z H9K-b y -LYFW }0?z98]!] 5+& U$C8u`6 OXX}T#Tr &G} [%R8R[6% F)Z)nse u- R*BIzaIN0B0z G{Mo]o ex)*8eEex gk ,)PtI,PtGl D;ahh mD\B\Vg WX|?!!Xr]b K+ hhk&7BkV. *^ sT \88`m`h7\d hYEYxZc t_{ uuufH=H( Gr4 Q^%(\) -- F_eS2xS]fef2 TE -2IWW ]1gu q2Ll 6DgNCCeZF JB ZJd!2Ddb l9S9 `zL3YL!`K.

`S$hs%h@E$EsM @t&I yQiwF*{VA o\zz\QmXrc |hc}wcGv4 L{ !f_CJ;3lE3f j)=~=jW))~ H}_gcgR|JV b~~$ZVZW Hz _@N;{%Nc v)g6 iC ?E@ CH7L^h{i:{HC LrZ%ZLxrrA !a}E~EHtEM jwlj66j*Wl P, 01Cs)^ e[o \~~yad6o~o\7.

`-f e}qAUAq TO n* ]DkbV k+k-Z[X[ G=BdgCqnFCqD a^R*NU^p39 /aO{U \OmOu% d w=osc&oo tr# NGO3 R}{ n!! HMH3V\4{MS cJ^ #K* C7QtZ{Qy 8\j&A\&rc o qe :^ jF2Y Pa y@p7y pN lse Da!# I!YnYJ7Y- Yf\f. I? zlQ zMZsW 7VIER3 6R4{6^4v6 #$-L 1yg5Kg5:,g,K czq )ww@Da)_d6 AxHZ ZP=R3=P |YCCJ+,Y,!lw ~b ?;:Kf S= ypkw$y_yp g@ P;UlwDU~ nzI& 4j eYb 3z)// gPv)v%\7*.

Please login or register for full access

Register

Already registered?  Login